 A message from Sideways Frequency |
|
BSEM: From Profitable Regenerative Leader to Advanced Wound Care Powerhouse with a Nasdaq Uplisting on the Horizon. BioStem Technologies (OTCQB: BSEM) continues to separate itself from the small-cap MedTech pack with seven straight profitable quarters, FDA-registered manufacturing, and clinically proven BioREtain® technology that drives superior healing outcomes in diabetic foot ulcers. The recent acquisition of BioTissue's surgical and wound care business adds $29 million in revenue, a national sales network, and immediate access to hospital and surgical settings, creating a direct path into acute and advanced wound care markets. With early adoption reflected in 40% year-over-year unit growth, a robust $300–$350 million market opportunity, and a potential Nasdaq uplisting in mid-2026, BSEM is executing on every element of a high-growth MedTech strategy. With a $25.50 price target from Zacks, BSEM stands out as a small-cap MedTech name with significant upside potential, especially as it prepares for a potential Nasdaq uplisting in 2026. Strong financial discipline, expanding commercial reach, and validated clinical results make BSEM a rare small-cap story to keep an eye on. |
| This message is a paid advertisement for BioStem Technologies (OTCQB: BSEM) from Sideways Frequency. Schaeffer's Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer's Investment Research Inc. and its principals are not affiliated with BioStem Technologies (OTCQB: BSEM). Schaeffer's Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer's Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer's Investment Research Inc. to buy or sell any security. Schaeffer's Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer's Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies (OTCQB: BSEM) on BioStem Technologies (OTCQB: BSEM) website for additional information. To stop receiving these emails, unsubscribe. |
Post a Comment
Post a Comment